Cancer risk is not increased after conventional hip arthroplasty

Figures & data

Table 1.  Numbers of patients (n) by age at operation, and number of person-years at end of follow-up

Age	Men		Women
	n	Person-years	n	Person-years
15–29	10	35	11	44
30–44	156	784	168	906
45–59	2,060	11,144	2,214	11,796
60–74	5,751	57,484	9,214	83,132
≥ 75	1,502	43,861	3,550	101,155
Total	9,479	113,308	15,157	197,033

Table 2.  Observed (Obs) numbers of cancer cases and standardized incidence ratios (SIRs) with 95% confidence intervals, by site

Primary site	Obs	SIR	95% CI
All sites	4846	0.95	0.92–0.97 ^a
Lip	50	1.19	0.88–1.56
Mouth, pharynx	104	1.09	0.89–1.30
Esophagus	49	0.81	0.60–1.06
Stomach	245	0.95	0.84–1.07
Colon	310	0.89	0.79–0.99 ^b
Rectum	193	0.91	0.79–1.04
Liver	65	0.87	0.67–1.11
Gall bladder	86	1.01	0.81–1.24
Pancreas	201	0.90	0.78–1.02
Larynx	19	0.80	0.48–1.25
Lung	368	0.65	0.58–0.71 ^a
Breast	515	1.00	0.92–1.08
Uterus, cervix	28	1.03	0.68–1.48
Uterus, corpus	134	0.94	0.79–1.10
Ovary	86	0.94	0.75–1.16
Prostate	843	1.09	1.02–1.16 ^b
Kidney	180	1.08	0.93–1.24
Bladder,ureter, urethra	222	0.98	0.86–1.11
Melanoma	97	0.99	0.80–1.20
Skin	279	1.07	0.95–1.20
Brain/nervous system	103	0.97	0.79–1.16
Thyroid	38	1.06	0.75–1.45
Bone	3	0.72	0.15–2.10
Connective tissue	24	0.90	0.58–1.34
Non-Hodgkin's lymphoma	167	0.92	0.79–1.06
Nodal non-Hodgkin's lymphoma	98	0.81	0.66–0.98 ^b
Hodgkin's lymphoma	13	1.26	0.67–2.15
Myeloma	90	1.14	0.92–1.40
Leukemia	96	0.85	0.69–1.03

^a p < 0.001; ^b p < 0.05.

Table 3.  Observed (Obs) numbers of cancer cases and standardized incidence ratios (SIR) with 95% confidence intervals (CI), by site and the time since the first total hip arthroplasty

Primary site				Time since operation
	0–2 years			3–10 years			11–20 years			> 20 years
	Obs	SIR	95% CI	Obs	SIR	95% CI	Obs	SIR	95% CI	Obs	SIR	95% CI
All sites	492	0.80	0.73–0.87 ^a	2560	0.95	0.92–0.98 ^b	1697	0.99	0.94–1.03	97	0.93	0.75–1.12
Stomach	31	0.82	0.55–1.15	134	0.95	0.80–1.11	79	1.07	0.85–1.33	1	0.24	0.01–1.34
Colon	30	0.79	0.53–1.12	165	0.92	0.78–1.06	107	0.87	0.72–1.04	8	1.01	0.44–1.98
Rectum	19	0.72	0.43–1.12	111	0.98	0.81–1.17	59	0.86	0.66–1.11	4	0.98	0.27–2.51
Pancreas	21	0.78	0.48–1.18	111	0.95	0.78–1.13	62	0.82	0.63–1.05	7	1.41	0.57–2.90
Lung, trachea	40	0.48	0.34–0.65 ^a	204	0.66	0.57–0.75 ^a	115	0.70	0.57–0.82 ^a	9	1.00	0.46–1.89
Breast	69	1.02	0.79–1.29	264	0.96	0.85–1.08	177	1.08	0.93–1.24	5	0.49	0.16–1.14
Female genital
organs	40	0.97	0.69–1.32	152	0.95	0.80–1.10	82	0.88	0.70–1.09	5	0.88	0.29–2.05
Kidney	20	0.91	0.56–1.41	100	1.11	0.90–1.34	55	1.05	0.79–1.36	5	1.65	0.53–3.84
Prostate	56	0.81	0.61–1.05	433	1.10	1.00–1.20	335	1.14	1.02–1.26 ^b	19	1.16	0.70–1.80
Melanoma	10	0.88	0.42–1.61	50	0.99	0.74–1.30	33	0.97	0.67–1.36	4	1.84	0.50–4.71
>Lymphoma,
leukemia	41	0.68	0.49–0.92	265	1.00	0.88–1.13	153	1.11	0.94–1.30	2	0.19	0.20–0.70 ^b

^a p < 0.001; ^b p < 0.05.